Raymond James & Associates Aldeyra Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 34,884 shares of ALDX stock, worth $168,140. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,884
Previous 34,633
0.72%
Holding current value
$168,140
Previous $114,000
64.91%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding ALDX
# of Institutions
116Shares Held
36.2MCall Options Held
196KPut Options Held
142K-
Perceptive Advisors LLC New York, NY9.28MShares$44.7 Million1.31% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$26.4 Million14.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$18.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$17.5 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.88MShares$9.07 Million0.24% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $281M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...